Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple Myeloma
This study has been completed.
Information provided by:
First received: May 8, 2002
Last updated: June 23, 2005
Last verified: March 2004
The primary goal of the study is to determine the best dose of an investigational drug to give to patients with multiple myeloma and to evaluate the investigational drug's effectiveness as a treatment for multiple myeloma.
Drug: Investigational drug
||Primary Purpose: Treatment
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Other specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary.
- Eligible patients must be at least 18 years of age with a diagnosis of multiple myeloma including elevated M-blood/urine protein or a tumor that can be evaluated by the doctor during the investigational drug's treatment.
- The patient's multiple myeloma must have gotten worse during/after previous chemotherapy was given.
- Any side-effects from prior chemotherapy must have subsided
- Blood and urine tests must show adequate bone marrow, liver, and kidney function.
Any of the following will exclude patients from study participation:
- indolent or smoldering myeloma or localized plasmacytoma
- hyperviscosity syndrome
- irradiation to 25% or more of bone marrow
- prior high dose chemotherapy with bone marrow or stem cell support
- current participation in other clinical trials
- pregnant or breast-feeding women
- known HIV-positive or AIDS-related illness
- patients planning to have radiation therapy or surgery that would interrupt study therapy in the next 6 months.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00036140
|Los Angeles, California, United States, 90048 |
|Los Angeles, California, United States, 90033 |
|Rancho Mirage, California, United States, 92270 |
|Cleveland, Ohio, United States, 44106 |
|Marshfield, Wisconsin, United States, 54449 |
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||May 8, 2002
||June 23, 2005
||United States: Food and Drug Administration
Keywords provided by Pfizer:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on December 05, 2013
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Blood Protein Disorders
Immune System Diseases